Incyte (INCY) Reports Q1 EPS of 12c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
May 9, 2016 7:00 AM EDT$183 million of 2016 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 59 percent growth over the same period last year. Full year Jakafi net product revenue guidance increased from a range of $800-815 million to a range of $815-830 million. Recent agreements with Lilly and Novartis allow development of ruxolitinib for the treatment of graft versus host disease (GVHD); U.S. pivotal trial expected to begin in the second half of 2016. Expanded European organization via acquisition of ARIAD Pharmaceuticals European business Diversified and growing portfolio of cancer... More
